Weight Loss Injection Raises Concerns Over Bone Density Loss
Amgen’s MariTide Faces Scrutiny After Early-Stage Trial Data
Shares of Amgen plummeted over 7% on Tuesday as analysts digested new data from an early-stage trial on its experimental weight loss injection, MariTide. The drug, a promising competitor in the weight loss market, is designed to be taken monthly and promotes weight loss differently than existing injections from Novo Nordisk and Eli Lilly.
Bone Mineral Density Loss Raises Red Flags
Analysts pointed to additional publicly available data from a phase one study showing that the highest dose of MariTide (420 milligrams) was linked to a roughly 4% loss of bone mineral density over 12 weeks. This decrease in bone mineral density can lead to weaker bones and a higher risk of fractures.
Experts Weigh In on Potential Risks
Cantor Fitzgerald analyst Olivia Brayer called the data a “big unknown” and suggested it could be a potential risk associated with drugs like MariTide, which work by using GIPR antagonism. However, Jefferies analyst Michael Yee downplayed the concerns, citing inconsistent data and the known side effect of bone mineral density changes in the first few months of weight loss treatment.
More Data Needed to Assess Safety Profile
BMO analyst Evan Seigerman urged caution in making judgments on MariTide’s safety profile based on this data alone, emphasizing the need for a larger cohort of patients to fully assess the drug’s risks. The full phase two trial data, set to be released before the end of the year, may provide more clarity on the issue.
Amgen’s Response and Next Steps
Amgen did not immediately respond to requests for comment on the data. As the company prepares to release crucial phase two trial results, investors will be watching closely for signs of MariTide’s potential safety risks and its competitiveness in the weight loss market.
Leave a Reply